The effect of intraperitoneal ropivacaine on postoperative pain and recovery after diagnostic laparoscopy and hysterosocopy: A Randomised Double Blind Placebo Controlled Trial
Description
Study Objective: To determine the effect of intraperitoneal ropivacaine on postoperative pain, nausea and recovery following diagnostic laparoscopy and hysteroscopy, women followed up for first eight hours after discharge. Design: Randomised Placebo Controlled Double Blinded Trial (Canadian Task Force Classification I) Setting: Single day case surgery hospital in Australia Patients: Well women aged 18 – 50 years, undergoing day case hysteroscopy and diagnostic laparoscopy for gynaecological indications. Interventions: 100mg intraperietoneal ropivacaine (intervention) or 100mg normal saline (placebo control) inserted intraperitoneally at the end of the procedure Measurements and Main Results: 59 patients included for analysis. 31 patients randomized to Ropivacaine and 28 patients to Control. Time to discharge was 20 minutes faster in patients randomized to Ropivacaine, however, this finding did not reach significance. Overall pain scores and nausea scores also showed no significant differences. There was no significant difference in opioid requirement between those receiving Ropivacaine versus controls. Conclusion: Intraperitoneal ropivacaine did not result in any significant pain, nausea or recovery time benefits when compared with control, in this randomized trial for women undergoing day case hysteroscopy diagnostic laparoscopy. No adverse effects of ropivacaine were identified. Trial was prospectively registered with the Australian Clinical Trials Registry trial number ACTRN12609000128291, date registered 23/02/2009